Compare Hims and Hers Health Inc (HIMS) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs 22nd Century Group Inc — how do they compare? Hims and Hers Health Inc trades at $30.92 (market cap $6.55B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Hims and Hers Health Inc is far larger — about 10536.1× 22nd Century Group Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and 22nd Century Group Inc for 32 Days on average.
| HIMS | XXII | |
|---|---|---|
Market Cap | $6.55B | $621.67K |
Volume | 14,842,814 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $62.76 | $483.00 |
52-Week Low | $14.52 | $0.80 |
Typical Hold Time | 21 Days | 32 Days |
Enterprise Value | $7.25B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.
The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
